2025-12-31 - Analysis Report
Okay, here's a breakdown of Procter & Gamble (PG) based on the data provided, with simple numbers and analysis:

**1) Return Rate Comparison**

*   **Company Overview:** Procter & Gamble (PG) is a multinational consumer goods corporation.
*   **PG Cumulative Return:** 25.78%
*   **S&P 500 (VOO) Cumulative Return:** 102.21%
*   **Divergence:** -76.8 (Relative Divergence: 3.4)

**Analysis:** PG has significantly underperformed the S&P 500 over the period covered by the cumulative return data.  The relative divergence of 3.4 indicates that the current divergence is near the lowest it has been historically (within the observed range).

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 21.0% | 7.9% | -8.0% | 0.0 | 215.0 |
| 2016-2018  | 9.0% | 67.3% | -6.0% | 0.1 | 215.1 |
| 2017-2019  | 24.0% | 70.4% | 2.0% | 0.3 | 292.3 |
| 2018-2020  | 27.0% | 78.8% | 4.0% | 0.4 | 325.7 |
| 2019-2021  | 41.0% | 78.8% | -5.0% | 0.5 | 382.9 |
| 2020-2022  | 13.0% | 79.4% | 13.0% | 0.6 | 354.7 |
| 2021-2023  | 26.0% | 79.4% | 24.0% | 0.4 | 343.0 |
| 2022-2024  | 9.0% | 79.4% | -12.0% | 0.4 | 392.4 |
| 2023-2025  | -18.0% | 80.1% | -85.0% | 0.1 | 337.1 |

*   **CAGR:** Compounded Annual Growth Rate. This varies considerably, including a recent negative value.
*   **MDD:** Maximum Drawdown. This has been high in recent periods.
*   **Alpha:** Measures performance relative to the market. The recent negative alpha suggests significant underperformance.
*   **Beta:** Measures volatility relative to the market. PG has a relatively low beta.
*   **Cap(B):** Market Capitalization in Billions.

**Analysis:** P&G's Alpha has been largely negative in recent years, indicating the stock has underperformed relative to its risk. Its Beta has been consistently below 1, indicating the stock is less volatile than the market average. The MDD indicates the risk the investor is taking.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 144.05
*   **Previous Close:** 144.57
*   **Change:** -0.36
*   **5-day SMA:** 144.21
*   **20-day SMA:** 143.67
*   **60-day SMA:** 147.17

**Analysis:** The stock price decreased slightly today. The 5-day SMA is above the 20-day SMA, suggesting a short-term upward trend, while both are below the 60-day SMA, indicating a longer-term downward trend.

**3) Indicators Analysis**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 63.78
*   **PPO:** 0.1894
*   **Hybrid Signal:** Buy 100% (7 shares - Very Safe)
*   **Recent Relative Divergence Change:** -4.6 (negative decline)
*   **Expected Return (%):** -8.1 (negative return compared to S&P 500)

**Analysis:** The MRI suggests a favorable investment environment (low risk), while the RSI indicates that the stock is approaching overbought territory, and the expected return is a negative figure.

**4) Recent News & Significant Events**

*   **Mixed Sentiment:** The news headlines present a mixed picture.  Cramer seems to favor the stock, but other articles point to recent price declines and investor concerns.
*   **Key Themes:** The news focuses on analyst opinions, price declines, and earnings performance.

**Analysis:** The news articles paint a mixed picture. Analyst opinions, like Cramer's, suggest potential long-term value, while articles about the stock hitting a 2-year low and investor concerns indicate current challenges.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (~1.92)
*   **Target Price:** 168.95 (Average)

**Analysis:** Analysts, on average, have a "Buy" rating with a target price well above the current price, suggesting upside potential. However, there is no record of recent rating changes.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-10-24 | 2.00 | 22.39 B$   |
| 2025-04-24 | 1.58 | 19.78 B$   |
| 2025-01-22 | 1.94 | 21.88 B$   |
| 2024-10-18 | 1.65 | 21.74 B$   |
| 2025-10-24 | 1.65 | 21.74 B$   |

**Analysis:** The EPS has been volatile, with a recent peak. Revenue also fluctuates, but the most recent quarter shows a relatively high figure.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $22.39B   | 51.37%        |
| 2025-06-30   | $20.89B   | 49.11%        |
| 2025-03-31   | $19.78B   | 50.98%        |
| 2024-12-31   | $21.88B   | 52.39%        |
| 2024-09-30   | $21.74B   | 52.06%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $53.27B   | 8.92%   |
| 2025-06-30   | $52.01B   | 6.95%   |
| 2025-03-31   | $52.27B   | 7.21%   |
| 2024-12-31   | $51.17B   | 9.05%   |
| 2024-09-30   | $51.84B   | 7.64%   |

**Analysis:** P&G maintains healthy revenue, robust profit margins, and a fairly consistent ROE.

**7) Comprehensive Analysis**

Overall, the analysis presents a mixed picture for Procter & Gamble:

*   **Underperformance:** PG has significantly underperformed the S&P 500. The stock is nearing oversold territory (low relative divergence).
*   **Mixed Market Sentiment:** The recent stock price has experienced a slight decrease, while analysts offer a positive outlook, but recent news indicates investor concern due to price declines.
*   **Healthy Financials:** P&G shows high investment recommendation from the MRI.
*   **Analyst Support:** Analysts have an overall "Buy" rating with a target price significantly above the current price.
*   **Earnings Volatility:** Recent EPS and revenue figures have fluctuated.

**Summary:**

PG's high MRI suggests the stock is currently undervalued. However, the expected return is negative compared to S&P 500.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.